Cargando…

Withdrawing Antipsychotics for Challenging Behaviours in Adults with Intellectual Disabilities: Experiences and Views of Prescribers

International current best practice recommends the discontinuation of antipsychotics for challenging behaviours in people with intellectual disabilities (ID), due to lack of evidence of efficacy and risks of harmful side-effects. In clinical practice, discontinuation may be difficult. The aim of thi...

Descripción completa

Detalles Bibliográficos
Autores principales:	de Kuijper, Gerda, de Haan, Joke, Deb, Shoumitro, Shankar, Rohit
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9779134/ https://www.ncbi.nlm.nih.gov/pubmed/36554973 http://dx.doi.org/10.3390/ijerph192417095

Ejemplares similares

Withdrawing Antipsychotics for Challenging Behaviours in Adults with Intellectual Disabilities: Experiences and Views of Experts by Experience
por: de Kuijper, Gerda, et al.
Publicado: (2022)

UK psychiatrists’ experience of withdrawal of antipsychotics prescribed for challenging behaviours in adults with intellectual disabilities and/or autism
por: Deb, Shoumitro, et al.
Publicado: (2020)

Association between epilepsy and challenging behaviour in adults with intellectual disabilities: systematic review and meta-analysis
por: Deb, Shoumitro, et al.
Publicado: (2020)

Causes of and Alternatives to Medication for Behaviours That Challenge in People with Intellectual Disabilities: Direct Care Providers’ Perspectives
por: Deb, Shoumitro (Shoumi), et al.
Publicado: (2022)

Support staff liaising effectively with professionals for the rational use of psychotropics for behaviours that challenge in adults with intellectual disabilities: Findings from a co-design event
por: Limbu, Bharati, et al.
Publicado: (2022)

Exploring the association of staff characteristics with staff perceptions of quality of life of individuals with intellectual disabilities and challenging behaviours
por: Bruinsma, Eke, et al.
Publicado: (2022)

Challenging behaviours: Views and preferences of people with intellectual disabilities
por: Wolkorte, Ria, et al.
Publicado: (2019)

Antipsychotics withdrawal in adults with intellectual disability and challenging behaviour: study protocol for a multicentre double-blind placebo-controlled randomised trial
por: Beumer, Sylvie, et al.
Publicado: (2021)

Improving knowledge of psychotropic prescribing in people with Intellectual Disability in primary care
por: Shankar, Rohit, et al.
Publicado: (2018)

Intellectual disability and antipsychotics
por: Iñiguez, I. Cuevas, et al.
Publicado: (2021)

Difficulties in Addressing Diagnostic, Treatment and Support Needs in Individuals with Intellectual Disability and Persistent Challenging Behaviours: A Descriptive File Study of Referrals to an Expertise Centre
por: de Kuijper, Gerda, et al.
Publicado: (2023)

Pharmacogenomics: an opportunity for personalised psychotropic prescribing in adults with intellectual disabilities
por: Perera, Bhathika, et al.
Publicado: (2022)

Non‐pharmacological interventions for challenging behaviours of adults with intellectual disabilities: A meta‐analysis
por: Bruinsma, E., et al.
Publicado: (2020)

Influence of the organizational environment on challenging behaviour in people with intellectual disabilities: Professionals’ views
por: Olivier‐Pijpers, Vanessa C., et al.
Publicado: (2018)

COVID-19-related prescribing challenge in intellectual disability
por: Rauf, Bushra, et al.
Publicado: (2021)

Aligning quality of life and guidelines for off-label psychotropic drugs in adults with intellectual disabilities and challenging behaviour
por: Laermans, P., et al.
Publicado: (2023)

Short-term PsychoEducation for Carers To Reduce Over Medication of people with intellectual disabilities (SPECTROM): study protocol
por: Deb, Shoumitro, et al.
Publicado: (2020)

Association between epilepsy and psychiatric disorders in adults with intellectual disabilities: systematic review and meta-analysis
por: Akrout Brizard, Basma, et al.
Publicado: (2021)

Cardiometabolic Effects of Antipsychotics in Challenging Behavior and Neuropsychiatric Symptoms in Patients With Intellectual Disability
por: Takano, Tomoyuki
Publicado: (2023)

Prescribing antipsychotic medication for adults with intellectual disability: shared responsibilities between mental health services and primary care
por: Paton, Carol, et al.
Publicado: (2022)

Short-Term Psycho-Education for Caregivers to Reduce Overmedication of People with Intellectual Disabilities (SPECTROM): Development and Field Testing
por: Deb, Shoumitro (Shoumi), et al.
Publicado: (2021)

Mental illness, challenging behaviour, and psychotropic drug prescribing in people with intellectual disability: UK population based cohort study
por: Sheehan, Rory, et al.
Publicado: (2015)

Support staff’s perceptions of discontinuing antipsychotics in people with intellectual disabilities in residential care: A mixed‐method study
por: Kleijwegt, Bas, et al.
Publicado: (2019)

COVID-19 pandemic impact on psychotropic prescribing for adults with intellectual disability: an observational study in English specialist community services
por: Naqvi, Danial, et al.
Publicado: (2021)

A Snapshot of Prescribing in Intellectual Disability CAMHS
por: Simpson, Struan
Publicado: (2022)

Perampanel and Challenging Behaviour in Intellectual Disability and Epilepsy: A Management Dilemma
por: Dolton, Emily, et al.
Publicado: (2014)

People with intellectual disabilities and harmful sexual behaviour: Professionals' views on the barriers to prevent harm
por: Svae, Gøril Brevik, et al.
Publicado: (2022)

Optimising medicines use in older adults with intellectual disability who have epilepsy: challenges and perspectives
por: O’Dwyer, Maire, et al.
Publicado: (2021)

Challenging behaviour in students with intellectual disabilities: the role of individual and classmates' communication skills
por: Hofmann, V., et al.
Publicado: (2022)

Evaluation of Serum Prolactin Levels in Intellectually Disabled Patients Using Antipsychotic Medications
por: Lambert, Tammy L, et al.
Publicado: (2012)

Metformin for the treatment of antipsychotic-induced metabolic disturbances in people with intellectual and developmental disabilities
por: Stogios, Nicolette, et al.
Publicado: (2023)

Audit of Adherence to Prescribing Guidelines of Psychotropic Drugs for People With Intellectual Disability and Behaviours That Challenge -Specialist Support Team -SST-Merseycare NHS Foundation Trust
por: Hasan, Syeda, et al.
Publicado: (2022)

Positive views on antipsychotic long-acting injections: results of a survey of community patients prescribed antipsychotics
por: Mace, Shubhra, et al.
Publicado: (2019)

Attributional styles of support staff working with people with intellectual disabilities exhibiting challenging behaviour
por: van den Bogaard, Kim J. H. M., et al.
Publicado: (2019)

Deprescribing psychotropic medicines for behaviours that challenge in people with intellectual disabilities: a systematic review
por: Adams, Danielle, et al.
Publicado: (2023)

Quality of prescribing of antipsychotic medication for people with intellectual disability under the care of UK mental health services: a cross-sectional audit of clinical practice
por: Paton, Carol, et al.
Publicado: (2016)

Morbidity and mortality of women and men with intellectual and developmental disabilities newly initiating antipsychotic drugs
por: Vigod, Simone N., et al.
Publicado: (2016)

Antipsychotic Use With and Without Comorbid Psychiatric Diagnosis Among Adults with Intellectual and Developmental Disabilities
por: Lunsky, Yona, et al.
Publicado: (2017)

Persons with Intellectual Disability: Sexual Behaviour, Knowledge and Assertiveness
por: Brkić-Jovanović, Nina, et al.
Publicado: (2021)

Under representation of people with epilepsy and intellectual disability in research
por: Shankar, Rohit, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_o6j9ls2tq1dqubfbqj3n1h8sn9